je.st
news
Tag: asco
ImmunoGen Surprises, PD-1 Drugs Under Scrutiny At ASCO
2015-06-02 03:40:01| Biotech - Topix.net
The biggest upside surprise from the American Society for Clinical Oncology meeting in Chicago, which ends Tuesday, probably came from , a beleaguered biotech that came back to life thanks to its antibody drug conjugate mirvetuximab soravtansine, or IMGN853. The drug's objective response rate - the percentage of tumors that shrank - was 53%, which induced several price-target increases and an upgrade to equal weight from Morgan Stanley.
Tags: drugs
scrutiny
surprises
asco
IntegraGen Presents Results of Two Studies during 2015 ASCO Meeting...
2015-06-01 20:27:19| Logistics - Topix.net
IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in oncology and autism, today announced the presentation of two studies during the 2015 American Society of Clinical Oncology Annual Meeting focusing on the association between miR-31-3p expression and clinical outcomes in metastatic colorectal cancer patients treated with panitumumab or cetuximab. The data presented further validates previous studies which have documented that miR-31-3p expression in the primary tumor of mCRC patients is predictive of the effect of anti-EGFR therapy.
Tags: results
studies
meeting
presents
ASCO Report Card: Grading Biotech and Cancer Drug Stocks
2015-06-01 16:19:45| Logistics - Topix.net
I spent a long weekend in chilly, rainy Chicago listening to endless cancer-drug data presentations at the American Society of Clinical Oncology annual meeting. Here are my flash impressions on the biotech and drug companies at this huge cancer conference, and whether they come out looking stronger or weaker.
Oncothyreon Breast Cancer Drug Exits ASCO '15 With Good Buzz
2015-06-01 14:09:24| Biotech - Topix.net
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 9+ You may proceed to the site by clicking here , however some pages might not work correctly.
Findings Presented at 2015 ASCO Annual Meeting Add to Breadth of KEYTRUDA (pembrolizumab) Data; Anti-Tumor Activity Now Demonstrated in 13 Different Tumor Types
2015-06-01 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. New Data Presented at ASCO in Multiple, Difficult-to-Treat Cancers, including Small Cell Lung, Esophageal and Ovarian Cancers Registrational Studies for KEYTRUDA Ongoing in Eight Different Tumor Types KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in multiple, difficult-to-treat cancers, including advanced small cell lung cancer (SCLC), esophageal cancer and ovarian cancer from the KEYNOTE-028 Phase 1b study. Language: English Contact: MerckMedia:Pamela Eisele, 267-664-0282orClaire Mulhearn, 908-200-1889orInvestors:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: add
data
types
presented
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] next »